

Herz

<https://doi.org/10.1007/s00059-020-04923-1>

Received: 13 April 2020

Revised: 14 April 2020

Accepted: 14 April 2020

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020

Stefan Möhlenkamp¹ · Holger Thiele²¹ Klinik für Kardiologie und Internistische Intensivmedizin, Bethanienkrankenhaus Moers, Moers, Germany² Universitätsklinik für Kardiologie, Herzzentrum Leipzig, Universität Leipzig, Leipzig, Germany

Ventilation of COVID-19 patients in intensive care units

About 5–15% of patients with COVID (corona virus disease)-19 infection require intensive care surveillance and ventilatory support. Current recommendations suggest early intubation of COVID-19 patients mainly for two reasons: (1) severe hypoxemia with $\text{PaO}_2/\text{FiO}_2$ often <200 mm Hg, fulfilling Berlin criteria of moderate-to-severe acute respiratory distress syndrome (ARDS); and (2) to protect staff from viral transmission [1, 2]. Mortality during mechanical ventilation appears to be high, however, and lung-protective ventilation is mandatory. Gattinoni et al. reported that many patients with COVID-19 pneumonia are initially characterized by a relatively well-preserved lung compliance despite severe hypoxemia, which is generally not observed in typical ARDS [3, 4]. Their concept of “L-type” and “H-type” pneumonia was presented at an ESICM webinar on April 2, 2020 [5]. These contributions and current recommendations form the basis of this brief review.

The proposed COVID-19 pathophysiology is given in more detail elsewhere [4]. In brief, viral infection may lead to subpleural inflammation, an increase in vascular permeability, and interstitial oedema. Impaired (regional) vasoreactivity with vasoplegia may counteract hypoxic vasoconstriction and further increase shunt fraction, which can be easily estimated (■ Fig. 1, ①). The physiologic response to hypoxemia is increased ventilation with increased tidal volume and an increase in respiratory rate. An increased metabolic drive from inflammation, high fever, and a rise in oxygen consumption and demand further increases respiratory drive and breathing work. Patients need careful surveil-

lance for early detection of deterioration (■ Fig. 1, ②). Biomarkers are helpful in assessing the clinical trend. Current suggestions reserve the use of high-flow nasal oxygen (HFNO) or noninvasive ventilation (NIV) for mild hypoxemia, with airborne precautions and a low threshold for intubation to avoid viral nosocomial transmission to staff [1]. In addition, similar to ventilator-induced lung damage (VILI), stress and strain on the lung associated with noninvasively generated high tidal volumes may also cause patient self-induced lung injury (P-SILI). Unlike ARDS, the majority of COVID-19 lungs are not small and stiff (“baby lung”), but have a near-normal compliance and will likely not benefit from high positive end-expiratory pressure (PEEP). For COVID-19 patients, the precise role of early HFNO or NIV therapy in moderate to severe hypoxemia should be clarified in a clinical trial setting with a special focus on viral transmission to healthcare workers.

In worsening hypoxemia, additional end-organ failure, or in the presence of contraindications such as delirium, invasive mechanical ventilation is required. Timely intubation should be carried out by the most skilled operator in a small drilled team, preferably avoiding bag-mask ventilation, using rapid sequence induction, video-laryngoscopy, personal protective equipment, and end-tidal capnometry. Ventilator settings initially with lower PEEP and higher tidal volume than in typical severe ARDS can be adapted with targets as indicated (■ Fig. 1, ③④), with a PEEP of 8 cm H₂O, driving pressure <15 cm H₂O, and a plateau pressure to achieve tidal volumes of about 8 ml/kg predicted body

weight especially in hypercapnic patients to begin with. The PEEP can then be gradually up-titrated to about 15 cm H₂O as needed (■ Fig. 1, ⑤), keeping driving pressure (ΔP) low. Importantly, ΔP is not simply the difference between PEEP and plateau pressure, but the resulting tidal volume (VT) should be normalized to the respiratory system compliance (CRS), i.e., $\Delta P = \text{VT}/\text{CRS}$, and hence be adjusted to the size of the aerated lung. Tidal volume too low for the size of the aerated lung may lead to hypoventilation and atelectasis. A low compliance indicates a functional baby lung and usually responds to higher PEEP (■ Fig. 1, ⑥). By contrast, COVID-19 patients often do not have baby lungs. Instead, they usually benefit from early prone positioning for 16 h or longer depending on the effect, in order to improve ventilation–perfusion (V/Q) mismatch by redistributing pulmonary perfusion (■ Fig. 1, ⑦). Indeed, the concept of *L-type* and *H-type* COVID-19 pneumonia was proposed because many patients initially have low elastance (= high compliance), a limited PEEP response and low recruitability, and a low V/Q matching (L-type).

Some patients may develop “hyperinflammation” and aggravation of pulmonary oedema, partly due to viral infection, bacterial superinfection, VILI or P-SILI, heart failure, fluid overload, multi-organ dysfunction, or a combination of all of these factors. Worsening inflammation may indicate transition toward the H-type, characterized by high elastance (= low compliance), a higher recruitability and PEEP response, and a high right-to-left shunt [4, 5], i.e. typical ARDS. These patients may benefit from a further stepwise increase in




Fig. 1 ◀ Illustration of a ventilation strategy for COVID-19 patients. SpO₂ O₂ saturation, NIV noninvasive ventilation, MV mechanical ventilation, PBW predicted body weight, pts patients, HFNO high-flow nasal oxygen, ΔP driving pressure, RR respiratory rate, ETCO₂ end-tidal CO₂, V_T tidal volume, PEEP positive end-expiratory pressure, CRs compliance of the respiratory system, kPa kilopascal (to convert to mm Hg, use factor 7.5), (vv-)ECMO veno-venous extracorporeal membrane oxygenation. (Modified from [5])

PEEP even beyond 15 cm H₂O every 15–30 min, or possibly from recruitment maneuvers (Fig. 1, 8). Neuromuscular blockade may improve transpulmonary pressure and has an anti-inflammatory effect. Fluids should be restricted depending on cardiac pre-load, with a negative daily balance to reduce pulmonary oedema. Heparin should be

given to prevent pulmonary embolism and micro-thrombosis in this presumably pro-thrombotic disease. Other causes of respiratory failure should be repeatedly assessed. Clinical evidence of neurotropic effects of the virus should not be missed. If oxygenation is still inadequate and the patient is deteriorating, vv-ECMO (veno-venous extracorporeal

membrane oxygenation) must be considered (Fig. 1, 9).

In summary, ventilation of COVID-19 ICU patients is challenging because of the heterogeneous lung pathology that requires an individualized lung-protective ventilation strategy to improve outcome.

Corresponding address

Prof. Dr. med. Stefan Möhlenkamp

Klinik für Kardiologie und Internistische
Intensivmedizin, Bethanienkrankenhaus Moers
Bethanienstr. 21, 47441 Moers, Germany
stefan.moehlenkamp@bethanienmoers.de

Conflict of interest. S. Möhlenkamp and H. Thiele
declare that they have no competing interests.

References

1. Phua J, Weng L, Ling L et al (2020) Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. *Lancet Respir Med.* [https://doi.org/10.1016/S2213-2600\(20\)30161-2](https://doi.org/10.1016/S2213-2600(20)30161-2)
2. Alhazzani W, Møller MH, Arabi YM et al (2020) Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Intensive Care Med.* <https://doi.org/10.1007/s00134-020-06022-5>
3. Gattinoni L, Coppola S, Cressoni M et al (2020) Covid-19 does not lead to a “typical” acute respiratory distress syndrome. *Am J Respir Crit Care Med.* <https://doi.org/10.1164/rccm.202003-0817LE>
4. Gattinoni L, Chiumello D, Caironi P et al (2020) COVID-19 pneumonia: different respiratory treatment for different phenotypes? *Intensive Care Med.* <https://doi.org/10.1007/s00134-020-06033-2>
5. Camporota L, Guerin C (2020) How to ventilate in COVID-19. https://esicm-tv.org/webinar1_live_20-how-to-ventilate-in-covid-19.html (ESICM-webinar on April 2nd). Accessed: 12 April 2020